Hodgkin Disease (Hodgkin's Disease)

Subscribe to Selected New Research on Hodgkin Disease

8931 relevant articles (656 outcomes, 1040 trials/studies) found for this Disease

Description: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

Also Known As:

Hodgkin's Disease; Hodgkins Disease; Granuloma, Hodgkin's; Granuloma, Hodgkins; Hodgkin's Lymphoma; Disease, Hodgkin; Disease, Hodgkin's; Disease, Hodgkins; Diseases, Hodgkins; Hodgkin Granuloma; Hodgkin Lymphomas; Hodgkin's Granuloma; Hodgkin's Lymphomas; Hodgkins Diseases; Hodgkins Granuloma; Hodgkins Lymphoma; Lymphogranulomas, Malignant; Lymphoma, Hodgkin; Lymphoma, Hodgkin's; Lymphomas, Hodgkin; Lymphomas, Hodgkin's; Malignant Granuloma; Malignant Granulomas; Malignant Lymphogranuloma; Malignant Lymphogranulomas; Granuloma, Hodgkin; Granuloma, Malignant; Hodgkin Lymphoma; Lymphogranuloma, Malignant

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Lymphoma: 23766

Hodgkin Disease: 8931

Hemic and Lymphatic Diseases

Lymphatic Diseases: 1961

Lymphoproliferative Disorders: 2359

Lymphoma: 23766

Hodgkin Disease: 8931

Immune System Diseases: 1319

Immunoproliferative Disorders: 26

Lymphoproliferative Disorders: 2359

Lymphoma: 23766

Hodgkin Disease: 8931

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma)
2.	Neoplasms (Cancer)
3.	Lymphoma (Lymphomas)
4.	Hodgkin Disease (Hodgkin's Disease)
5.	Leukemia

Experts

1.	Diehl, V: 21 articles (09/2007 - 01/2000)
2.	Younes, Anas: 20 articles (08/2008 - 01/2002)
3.	Engert, Andreas: 19 articles (02/2008 - 01/2002)
4.	Diehl, Volker: 19 articles (01/2008 - 01/2002)
5.	Engert, A: 15 articles (02/2007 - 01/2000)
6.	Medeiros, L Jeffrey: 12 articles (03/2008 - 05/2002)
7.	Stein, Harald: 10 articles (10/2008 - 04/2002)
8.	Brice, Pauline: 9 articles (03/2008 - 01/2002)
9.	Dörken, Bernd: 8 articles (10/2008 - 04/2002)
10.	Fermé, Christophe: 8 articles (03/2008 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hodgkin Disease:

1.	MOPP protocolIBA 01/01/1991 - "The drug regimen LOPP appears to be as effective as MOPP in producing complete remission and long term survival in patients with advanced Hodgkin's disease." 07/01/1983 - "Our results indicate that ABDIC is a potentially curative regimen for a fraction of patients with MOPP-resistant Hodgkin's disease who achieve complete remission with prior MOPP therapy. " 05/01/1979 - "We conclude that patients with Hodgkin's disease who relapse after a first complete remission induced by MOPP are not necessarily resistant to further MOPP therapy and can achieve long-term survival with MOPP reinduction." 06/01/1978 - "In this series of patients ABVD was not an effective curative regimen for patients with Hodgkin's disease who have failed MOPP." 03/01/1989 - "ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity." Order ALL the reference details at left...
2.	Doxorubicin (Adriamycin)FDA LinkGeneric 02/15/2002 - "Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen." 04/01/2007 - "A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)." 09/01/1995 - "Non-Hodgkin lymphomas (NHL) of intermediate and high-grade malignancy respond well to doxorubicin-containing regimens, but long-term survival does not exceed 30% in large studies with long-term follow-up. " 01/01/1990 - "Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial." 01/01/1983 - "[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]" Order ALL the reference details at left...
3.	Bleomycin (Blenoxane)FDA LinkGeneric 07/01/1997 - "This study summarized results of treatment of the extraperitoneal lymphatic nodes in patients with Hodgkin's disease with infusion of oily form of bleomycin into the lymphatic vessels. " 07/01/1997 - "[A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes]" 10/20/2005 - "Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma." 03/01/2005 - "Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease." 07/01/1999 - "Life threatening lung toxicity induced by low doses of bleomycin in a patient with Hodgkin's disease." Order ALL the reference details at left...
4.	Vincristine (Oncovin)FDA LinkGeneric 01/01/2000 - "Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial." 11/01/2001 - "We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine. " 06/15/1984 - "Vincristine infusion may afford palliation for patients with advanced non-Hodgkin's lymphomas who have become refractory to standard chemotherapeutic regimens even if they have received prior vincristine by conventional bolus injection. " 11/01/1982 - "The case history of a 24-year-old male with the nodular sclerosing form of Hodgkin's disease (stage IIE) who accidentally received an overdose of vincristine (25 mg, 0.39 mg/kg) is reported. " 04/08/1982 - "Fifteen patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface, during the first week of each month for 3 months). " Order ALL the reference details at left...
5.	Prednisone (Sone)FDA LinkGeneric 10/31/1962 - "[Effect of large doses of prednisone on the clinical course of advanced forms of Hodgkin's disease.]" 12/01/1957 - "[Acute malignant lymphogranuloma and its treatment with prednisone.]" 12/18/1976 - "The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. " 01/01/2000 - "The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?" 08/16/1975 - "Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. " Order ALL the reference details at left...
6.	Vinblastine (Vinblastine Sulfate)FDA Link 05/01/1979 - "randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease." 06/01/1972 - "A randomized study of irradiation and vinblastine in stages I and II of Hodgkin's disease. " 10/01/1992 - "Moreover, the patients with Hodgkin's disease received a mean total dose of 84 mg of vinblastine. " 11/11/1974 - "[Use of vinblastine in Hodgkin's disease]" 04/01/1974 - "Vinblastine treatment of Hodgkin's disease. " Order ALL the reference details at left...
7.	Procarbazine (Matulane)FDA Link 04/01/1991 - "In the other, the RRM attacks may have been associated with procarbazine therapy applied for Hodgkin's disease. " 09/01/1979 - "Procarbazine [N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride] is used to treat Hodgkin's disease. " 02/01/1979 - "From the incidence of patients with Hodgkin's disease (1 : 42 000) the calculated population dose of procarbazine is 5.12 micrograms/kg. Assuming equal sensitivity between the sexes we can calculate, for an estimated number of 30 000 genes, the induction of about 22 mutations per million children due to procarbazine treatment. " 02/01/1979 - "Procarbazine is used in drug-combination treatment of Hodgkin's disease. " 02/08/1971 - "Procarbazine in the management of late Hodgkin's disease." Order ALL the reference details at left...
8.	Etoposide (VP 16)FDA LinkGeneric 11/15/1998 - "The effects of etoposide on testicular function in boys treated for Hodgkin's disease." 03/01/1993 - "This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease." 12/01/1992 - "Etoposide in the treatment of non-Hodgkin's lymphomas." 01/01/1990 - "The case of Vepesid overdosage in a patient with Hodgkin's disease." 01/01/1982 - "It is concluded that etoposide has significant activity particularly in Hodgkin's disease. " Order ALL the reference details at left...
9.	Dacarbazine (DIC)FDA LinkGeneric 06/01/1990 - "DIC after bone marrow harvesting in a patient with Hodgkin's disease in remission." 12/01/2003 - "A psu dic(17;2)(p11.2;p21), leading to p53 deletion, was observed in a patient who developed a mixed cellularity Hodgkin's disease coexisting with the CLL/SLL in the same lymph node. " 12/22/1978 - "[DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)]" 11/01/2009 - "5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) is an atypical alkylator used as standard treatment in human Hodgkin's lymphoma, and has been effective in combination treatment to treat resistant lymphoma in dogs. " 02/01/2002 - "Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. " Order ALL the reference details at left...
10.	Mechlorethamine (Nitrogen Mustard)FDA Link 10/01/1970 - "Long-term remission in Hodgkin's disease after nitrogen mustard therapy." 11/01/1959 - "[Clinical studies on nitrogen mustard and roentgen therapy of Hodgkin's disease.]" 05/01/1998 - "[Hodgkin's disease in two children of mother treated with nitrogranulogen]" 07/01/1987 - "The data suggest that mutagenesis by this combination of drugs which is used extensively in treating Hodgkin's disease is due primarily to the mechlorethamine and that the frequency of mutation-induction may be a function of the order of administration." 11/05/1956 - "[Use of sanamycin and triethylenemelanine or of nitrogranulogen in malignant granuloma.]" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 05/01/2008 - "Most patients with Hodgkin lymphoma (HL) can be cured with initial multiagent chemotherapy. " 01/01/2008 - "With the application of modern chemotherapy and radiation techniques, most patients with Hodgkin lymphoma can be cured, regardless of initial extent of disease. " 10/01/2005 - "Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. " 11/01/2003 - "The sensitivity of pediatric Hodgkin disease to radiation and chemotherapy has resulted in cure for most children and adolescents who have been diagnosed in the past three decades. " 02/01/2002 - "CONCLUSION: These data confirm our preliminary report that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally extensive and advanced Hodgkin's disease. " Order ALL the reference details at left...
2.	Combination Drug Therapy (Combination Chemotherapy) 07/15/1995 - "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy. " 09/01/1988 - "Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtypes of non-Hodgkin's lymphomas. " 02/01/1992 - "PATIENTS AND METHODS: Study population comprised 107 patients with Hodgkin's disease treated with combination chemotherapy at the National Cancer Institute who relapsed after achieving a complete remission. " 01/01/1991 - "Initial results from studies with third-generation combination chemotherapy regimens for the treatment of aggressive non-Hodgkin's lymphomas (NHL) demonstrated complete remission (CR) rates higher than those reported with first-generation regimens. " 08/01/2004 - "Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy." Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 08/01/1989 - "The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432 patients achieving complete remission after treatment for stage I and II Hodgkin's disease at the Royal Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. " 01/01/1983 - "Peripheral lymphocyte chromosomes were analyzed in 55 consecutive patients with complete remission after treatment for Hodgkin's disease. " 01/01/1993 - "Eleven months after treatment, both Wegener's disease and Hodgkin's lymphoma remained in remission." 10/01/1984 - "Testicular function in young men in long-term remission after treatment for the early stages of Hodgkin's disease." 03/01/1984 - "Ovarian function in young women in long-term remission after treatment for Hodgkin's disease stage I or II." Order ALL the reference details at left...
4.	Stem Cell Transplantation 01/01/1999 - "High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission." 02/01/1998 - "Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index." 05/01/2006 - "We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n = 9; MSD, n = 12). " 02/01/2003 - "Clinical and translational research initiatives that hold promise for children with Hodgkin disease in the future include: use of the WHO Classification System combining morphologic and biologic criteria; noninvasive staging procedures with increased sensitivity and specificity; development of a useful prognostic index to define groups for risk-adapted therapy; high-dose therapy with stem cell transplantation; and novel therapies." 10/01/1999 - "PURPOSE: To investigate the results of high-dose therapy and autologous stem-cell transplantation (ASCT) in adults with Hodgkin's disease who do not enter remission after induction therapy, to determine overall survival (OS) and progression free survival (PFS), and to identify prognostic factors. " Order ALL the reference details at left...
5.	Splenectomy 01/01/1997 - "We have carried out a study of the bone marrow status in both irradiated and non-irradiated zones of 56 patients with stage I-II Hodgkin's disease in complete 9-12 (33 patients, group 1) and 18-23 (23 patients, group 2) year remission after therapeutic irradiation of the supradiaphragmatic lymphatic collectors at a dose of 40 Gy with irradiation of the spleen (33 patients) or splenectomy (23 patients). " 05/01/1987 - "A study was made of the bone marrow status in unirradiated zones of 33 patients with stage I-II Hodgkin's disease in complete 9-12 year remission after therapeutic irradiation of the lymphatic collectors of the upper part of the trunk in combination with irradiation of the spleen (16 patients) or splenectomy (17 patients). " 10/01/1981 - "[Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission]" 07/01/1980 - "In each of these patients the Hodgkin's disease was in complete remission, and each had a previous splenectomy. " 01/01/1978 - "Investigations were carried out on the effects of splenectomy on the immune state of patients with Hodgkin's disease during remission. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hodgkin Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 656 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>